These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 3892051)

  • 1. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Lamm DL
    J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
    deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
    J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer.
    Torrence RJ; Kavoussi LR; Catalona WJ; Ratliff TL
    J Urol; 1988 May; 139(5):941-4. PubMed ID: 3361668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder cancer immunotherapy.
    Lamm DL; Thor DE; Stogdill VD; Radwin HM
    J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Sarosdy MF; Lamm DL
    J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
    Brosman SA
    J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Catalona WJ; Hudson MA; Gillen DP; Andriole GL; Ratliff TL
    J Urol; 1987 Feb; 137(2):220-4. PubMed ID: 3806806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ.
    Brosman SA
    J Urol; 1985 Jul; 134(1):36-9. PubMed ID: 3892049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
    Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
    J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin.
    Bretton PR; Herr HW; Kimmel M; Whitmore WF; Laudone V; Oettgen HF; Fair WR
    J Urol; 1990 Apr; 143(4):710-2; discussion 712-3. PubMed ID: 2313796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical bacillus Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder.
    Pansadoro V; De Paula F
    J Urol; 1987 Aug; 138(2):299-301. PubMed ID: 3599242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin.
    Kelley DR; Haaff EO; Becich M; Lage J; Bauer WC; Dresner SM; Catalona WJ; Ratliff TL
    J Urol; 1986 Feb; 135(2):268-71. PubMed ID: 3511285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.